ARDELYX INC. - COMMON STOCK

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

03 Jan 2024 05:03:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

20 Dec 2023 05:00:00 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

21 Nov 2023 13:02:00 By Nasdaq GlobeNewswire

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

21 Nov 2023 05:01:45 By Nasdaq GlobeNewswire

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

15 Nov 2023 13:02:00 By Nasdaq GlobeNewswire

Ardelyx Announces Departure of Board Member

13 Nov 2023 13:02:00 By Nasdaq GlobeNewswire

Ardelyx to Participate at the Jefferies London Healthcare Conference

10 Nov 2023 05:05:00 By Nasdaq GlobeNewswire

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

06 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

03 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

31 Oct 2023 04:00:01 By Nasdaq GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

30 Oct 2023 14:42:57 By Nasdaq GlobeNewswire

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

23 Oct 2023 05:07:01 By Nasdaq GlobeNewswire

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

18 Oct 2023 13:02:39 By Nasdaq GlobeNewswire

Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital

17 Oct 2023 16:23:38 By Nasdaq GlobeNewswire

FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor

17 Oct 2023 16:01:06 By Nasdaq GlobeNewswire

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA

13 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

04 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

28 Sep 2023 05:02:00 By Nasdaq GlobeNewswire

Tenapanor for Hyperphosphatemia Approved in Japan

25 Sep 2023 01:15:13 By Nasdaq GlobeNewswire

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

11 Sep 2023 05:00:00 By Nasdaq GlobeNewswire